

Advancing Health Research Through Collaboration

Annual Report 2016-17

BioGrid Facts

137 representing 75 institutions **5107**

Number of Members at 30 June 2017

Active research projects represented across all states and the ACT

Journal publications reported to date that have utilised BioGrid for their research

204



Contents

Members and Collaborators	2
Chairman's Report	4
Chief Executive Officer's Report	5
About BioGrid	6
Projects	
VCCC Cancer Health Data Platform	8
Type 1 Diabetes Database Funding	8
Improving Diabetes Outpatient Care	9
PURPLE Created To Support Pancreatic Cancer Research	9
CART-WHEEL Partnered With The International Waldenström's Macroglobulinemia Foundation	10
Student Project	11
Directors' Report	12
Financial Report	17
Directors' Declaration	22
Auditor's Report	22

Members and Collaborators

BioGrid Australia Ltd is a not for profit company limited by guarantee. Its members are health services, universities and research institutes. At the time of this report, BioGrid's overarching evergreen collaboration agreement has been executed with 37 institutions (representing 75 sites across Australia) covering the management of governance, intellectual property, data access, undertaking projects, commercialisation and publications.





* Non-member collaborator



Chairman's Report

Although it was a challenging year financially for BioGrid, the Board's concerted strategic efforts promoted growth of the BioGrid brand and extended the research community's understanding of our capabilities. The trust we have earned over our many years of successful operation, and the regard in which our services are held, allowed us to finish the year with the confidence to continue and grow the business.

BioGrid's principal activity is data sharing to advance health research through the linking of privacy-protected and ethically approved clinical, imaging, biospecimen and genetic data among a wide network of health collaborators. During the year those activities continued and we now regularly use our technology to support platforms and registries accessed by clinicians to support their decision making for individual patients.

Usage of BioGrid's services has increased this year and clinical institutions and administrators as well as researchers are now beginning to understand the value of the unique linkage services we offer. We exceeded benchmarks for journal publications and approved active research projects and enabled many firsts in the linkage of clinical data, such as the Victorian Comprehensive Cancer Centre Platform's linkage of primary care data.

The non-executive management of BioGrid commenced very positively with the appointment of Professor Karin Verspoor as director on the BioGrid Board during August 2016. Karen is the Deputy Head of Department (Operations) of the Department of Computing and Information Systems at the University of Melbourne, a Fellow of the Melbourne Business School and Deputy Director of Health and Biomedical Informatics Centre. Her expertise is welcomed, both in health information technology and in business. She has made a valuable contribution to technical and strategic discussions and the Board is grateful for her contribution. At the end of this year, we increased the BioGrid collaboration to 37 members and collaborators as we welcomed South Western Sydney Local Health District (Campbelltown, Liverpool, Bankstown Hospitals), Northern Adelaide Local Health Network (Lyell McEwin, Modbury Hospitals) and the University of Western Australia.

Special thanks to Julian Clark and David Polonsky for their continued dedication to the Audit and Risk Committee, Julian as inaugural Chair and David as current Chair. The ongoing contribution and cooperative work of the Member Management Committee and the Scientific Advisory Committees over the past year has been outstanding and must be acknowledged.

The entire BioGrid team worked tirelessly to overcome this year's financial hurdles. Each and every person involved has contributed to the positioning of BioGrid to grow and support more critical research and clinical decision making to improve outcomes for patients.



Chief Executive Officer's Report

For over a decade the BioGrid collaboration has helped researchers to investigate questions that could not be explored without BioGrid's ethically approved data linkage platform. In turn, patients have benefited from published studies that guide clinicians' decision making. This year BioGrid's strength in linkage has been applied to larger projects that will deliver real improvements in patient care in real time.

A BUPA Foundation grant awarded to the Victorian Comprehensive Cancer Centre (VCCC) funded research into the continuum of cancer care that utilises BioGrid's unique data linkage service. The Primary Care Cancer Research Group collaborated with the VCCC in the VCCC Cancer Health Data Platform project, the first large-scale, comprehensive data linkage that connects primary care and hospital data for cancer patients.

This year we welcomed the Northern Adelaide Local Health Network (NALHN) as a member, and assisted them with their utilisation of the BioGrid Diabetes Clinical and Research Database to move diabetes outpatient care into the 21st century. In addition to our linkage and governance capabilities, BioGrid also provided consulting services in a number of activities related to data collection and analysis. These professional services add a great deal of value to our members and are a service offering we would like to expand in future.

Last year CART-WHEEL (the Centre for Analysis of Rare Tumours) added its first set of disease specific questions as a part of the WhiMSICAL study. This year, the study was rolled out via the International Waldenström's Macroglobulinemia Foundation (IWMF), a patient founded and led, non-profit organisation dedicated to supporting everyone affected by Waldenström's Macroglobulinemia (WM) and advancing the search for a cure. Also, following patient feedback, further enhancements for graphical presentation of test results and online consent have been implemented. The enhancements have been jointly funded by Concord Cancer Centre, NSW and WM Australian patients. The PURPLE Translational Registry (Pancreatic Cancer: Understanding Routine Practice and Lifting End Results) was created this year by Dr Belinda Lee who commissioned BioGrid to build the registry software and provide data linkage and reporting services for the project. It is the first translational registry in pancreatic cancer and it is a multisite, multidisciplinary, prospective database that will bring together clinical data from centres in Australia, New Zealand and Singapore. PURPLE uses BioGrid's federated data sharing platform to accelerate progress by enabling the sharing of comprehensive, de-identified clinical data that has been securely collected to a defined standard.

None of these achievements would have been possible without the entire BioGrid team. A special thanks to the Board directors, BioGrid member representatives and collaborators and in particular the very dedicated team of BioGrid staff at the heart of the organisation.


About BioGrid

Data governance, security and ethics are at the core of BioGrid's federated data sharing platform that securely links patient level clinical, biospecimen, genetic and imaging data sets across multiple sites and diseases for the purpose of medical research.

BioGrid's infrastructure and data management strategies address the increasing need by authorised researchers to dynamically extract and analyse data from multiple sources whilst protecting patient privacy.

In the health sector, BioGrid is a trusted independent virtual real-time data repository. Investment in BioGrid has facilitated a combination of technology, collaboration and ethics approval processes for data sharing that exist nowhere else in the world.

For more information on how BioGrid works, what data is linked to BioGrid and how to access data, go to **www.biogrid.org.au**





- 1. Patient information is recorded in one or more data sources (i.e. databases, spreadsheets), which are stored on a collaborating institution's computer network. This information comprises clinical health information data and identifiers.
- 1a. Clinical health information data are the collection of facts and opinions about an individual's health and wellbeing. Treatment details are an example of clinical health information data.
- **1b.** Identifiers are the data items, which identify the individual who is described within a patient record. A patient's name is an example of an identifier.
- 2. The patient information is copied into replica data sources, which are stored on the collaborating institution's Local Research Repository (LRR), on a nightly basis or frequency agreed by the collaborating institution.
- A limited set of identifiers from each new patient record are sent from the replica data sources to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection.
- 4. The Linkage Key Federator (LKF) forwards the identifiers to BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.
- The identifiers are compared with the USI database's records to establish whether data about the patient already exists within a BioGrid-linked data source.

If a match is found for a patient's data, the patient has previously been allocated a USI. If no match is found for a patient's data, the patient's set of identifiers and a new USI are written to the USI database.

- 6. The USIs for the matching and non-matching patients are sent back to the LKF.
- The USIs are sent back to the LRR via a secure encrypted VPN connection and stored with their associated clinical health information data.

- 8. Once authorised access via the BioGrid Australia Data Access Application System has been provided to the researcher, they can commence querying the de-identified data they have approval to access.
- 9. The researcher submits a data query to BioGrid Australia's statistical analysis (SAS) computer via the Internet.
- 10. The SAS computer forwards the query to the FDI.
- **11.** The FDI requests the specified data from each of the relevant LRRs via a secure encrypted VPN connection.
- The clinical health information data and USIs from applicable patient records are sent to the FDI via a secure encrypted VPN connection. These data are combined into a temporary table. The table is removed from the FDI upon completion of the query.
- **13.** The SAS computer reads and processes data from the temporary table.
- **14.** The SAS computer presents the results of the query to the researcher.

BioGrid provides alternative matching methodology referred to as exact matching using a cryptographic hashing function when individual identifiers cannot be brought together in one place for comparison.

- Highly secure hash generating software is installed at collaborating institution. The hashing algorithm is run at collaborating institution's site on the replica data sources. A unique hash value is created for each set of identifying patient data. No identifying information ever leaves the source site.
- Unique hash value from each new patient record is sent from the replica data source to BioGrid Australia's Linkage Key Federator (LKF) via a secure encrypted Virtual Private Network (VPN) connection. No identifying information ever leaves the source site.
- The LKF synchronises its matches with the BioGrid Australia's Linkage Key server. This server hosts the Unique Subject Identifier (USI) database.

Projects

VCCC Cancer Health Data Platform

The Victorian Comprehensive Cancer Centre (VCCC) received a BUPA Foundation grant for the Primary Care Cancer Research Group's research into the continuum of cancer care.

The Primary Care Cancer Research Group collaborated with the VCCC in the VCCC Cancer Health Data Platform project, the first large-scale, comprehensive data linkage that connects primary care and hospital data for cancer patients.

This important project will ultimately improve cancer care and patient outcomes by supporting the development of an innovative and responsive data strategy to enhance cancer health services research capability. Utilising BioGrid's data linkage and governance capacity, the platform will be available to health services and other clinical cancer researchers. There will be two phases of the project, each adding new linkages to registries and a variety of other data sets.

Type 1 Diabetes database funded by the Juvenile Diabetes Research Foundation

The Australasian Diabetes Database Network (ADDN) was this year funded by the Juvenile Diabetes Research Foundation, enabling the capture of clinical data from thousands of people living with Type 1 diabetes on a single database. This development is another important step towards the goal of improving outcomes for people with Type 1 diabetes.

Diabetes clinics and hospitals use clinical databases to capture health information from people with T1D. ADDN is a way of bringing together de-identified data from multiple clinics onto BioGrid's national platform, to foster collaborative research and improve clinical care.

This allows for routine surveillance of clinical outcomes at a multi-national level and also provides an opportunity for researchers to address important clinical questions in diabetes care. The data in ADDN offers many possibilities for improving clinical care – researchers can see how T1D progresses over time, when complications most commonly develop, and how different models of care impact on outcomes.

ADDN forms part of an Australasian data ecosystem, linking health, demographic and administrative datasets to better understand health outcomes for people living with chronic conditions. This growing evidence base places ADDN in a unique position to evaluate the impact of major investments, such as the Australian Government Continuous Glucose Monitoring (CGM) program and the JDRF-administered Insulin Pump Program.

Improving Diabetes Outpatient Care

The Northern Adelaide Local Health Network (NALHN) utilised the BioGrid Diabetes Clinical and Research Database in a project aimed at moving diabetes outpatient care into the 21st century.

NALHN represented by Lyell McEwin and Modbury hospitals implemented one web-based application available from each hospital site's intranet for the collection and management of patient information to support clinical care, audit and research projects.

In addition to providing the platform to share de-identified data with other members of the BioGrid collaboration and other research parties, BioGrid provided consulting services. Support included: facilitated communication permitting internal and external report generation; consulting with clinicians to deliver some standardisation in data collection; and developing the basis for data collection, analysis and benchmarking.

PURPLE created to support pancreatic cancer research

The PURPLE Translational Registry (Pancreatic Cancer: Understanding Routine Practice and Lifting End Results) was created this year by Dr Belinda Lee who commissioned BioGrid to build the registry software and provide data linkage and reporting services for the project.

This multi-site, multi-disciplinary translational pancreatic cancer registry is the first of its kind and aims to increase data sharing and collaboration across cancer centres and research laboratories to relocate novel research findings from "bench-to-bedside".

Although currently the 5th most common cause of cancer death in Australia, pancreatic cancer is predicted to become the 2nd leading cause of cancer deaths globally by 2030. PURPLE was developed to combat this alarming trend. Major issues being tackled include improving existing detection methods and developing more effective therapies.

PURPLE is powered by BioGrid Australia technology, which ensures data protection, site privacy and patient confidentiality. To progress its establishment aims, PURPLE underpins a wide range of translational studies. The registry supports tissue and blood-based studies, registry-based clinical trials, and biomarker studies including the DYNAMIC-Pancreas clinical trial and the pancreatic cancer organoid program.

Projects

CART-WHEEL partnered with the International Waldenström's Macroglobulinemia Foundation

In 2015-16 CART-WHEEL (the Centre for Analysis of Rare Tumours) added its first set of disease specific questions as a part of the WhiMSICAL study. This year, the study was rolled out via the International Waldenström's Macroglobulinemia Foundation (IWMF), a patient founded and led, non-profit organisation dedicated to supporting everyone affected by Waldenström's Macroglobulinemia and advancing the search for a cure.

Waldenström macroglobulinemia (WM) is a rare type of slow-growing, non-Hodgkin lymphoma with reports showing approximately 1000-1500 new cases occurring each year in the U.S. It causes overproduction of a protein called monoclonal immunoglobulin M (IgM or "macroglobulin").

At this time, there is no known cure for WM. However, several treatment options are available to prevent or control the symptoms of the disease including plasma exchange, chemotherapy, and/or biological therapy.

CART-WHEEL.org has teamed up with the Waldenström's Macroglobulinemia Community globally through the International Waldenström's Macroglobulinemia Foundation (IWMF) and in Australia through WMozzies. These collaborations are assisting to better understand the nature of this rare disease and the patients' response to currently used treatments in Australia and internationally by generating data through CART-WHEEL questionnaire.

CART-WHEEL this year also welcomed participants who are at increased risk of cancer due to a gene or inherited cancer syndrome.

Student Project

For a number of years BioGrid has enjoyed a mutually beneficial relationship with La Trobe University's College of Science, Health & Engineering, School of Psychology & Public Health. Student's on placement have the opportunity to test and improve their skills in a real-world environment and BioGrid benefits from their good work.

For a number of years BioGrid has enjoyed a mutually beneficial relationship with La Trobe University's College of Science, Health & Engineering, School of Psychology & Public Health. Student's on placement have the opportunity to test and improve their skills in a real-world environment and BioGrid benefits from their good work.

This year Bing Toh joined our team and explored the application of the SAS data analytical tool. SAS analytical tools are used to provide researchers with the ability to extract required linked data and perform analyses, allowing for the creation of queries to answer the desired research question.

Focusing on the head and neck database, Bing examined the functionalities and benefits of SAS analytics, based on the extraction, manipulation and mapping of the data. He also considered how health information managers and health professionals can utilise SAS through data extraction and manipulation.

Bing created a dashboard for the head and neck database which included the ability to graph age and gender plus social factors such as tobacco and alcohol use. These graphic representations allow researchers to picture the data, improving their ability to understand its meaning. With the visualisation of data, new questions arise and researchers are able to raise new queries to investigate the questions. He was also able to apply SAS analytics to episode diagnosis to the exploration of tumour sites which int urn enabled the analyse the rate of survival by tumour site. He found that the extraction of different categorical variables from different tables can determine whether there is an association between the variables within the demographic data for the head and neck cancer database. The extraction process of health data allows the extraction and analysis of relevant data.

The data mapping tools provide a graphical visualisation of the extracted data, enabling health information managers and health professionals to gain a better understanding of the data. Health professionals can also use the extraction and graphing system to better inform clinical decision making.

Health information managers can use the tools to improve the management and communication of health information. It may even be possible to cut costs by improving the quality and rapidity of clinical decisions.

Dr Leon Heffer supervised Bing, as he supervised previous students.

Directors' Report

The directors present their report on BioGrid Australia Limited for the financial year ended 30 June 2017.



Professor Bryan Williams PhD, Hon FRSNZ

Director and Chairman since March 2009

Emeritus Director and Distinguished Scientist, Hudson Institute of Medical Research, 2017–present

Institute Director and CEO, Hudson Institute of Medical Research (2014–2017)

Director, Monash Institute of Medical Research (2006–2013)

Director, Pacific Edge Ltd (New Zealand) (2013–present)

Director, Pacific Edge Pty Ltd (Australia) (2008–present)

Director, Cancer Trials Australia Pty Ltd, (2009–2014)

Director and Chairman, MEI Pharma Inc. (2006–2013)

Member of the Victorian Cancer Agency Consultative Council (2009–2012)

Director, Centre for Cancer Research, Monash Institute of Medical Research (2006–2012)

Professor, Department of Genetics, Case Western Reserve University, Cleveland, USA, (1993–2005)

Chairman, Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation in Cleveland, USA, (1991–2005)



Dr Julian Clark BSc (Hon), PhD, MAICD, FTSE

Director since March 2009

Head of Business Development, The Walter and Eliza Hall Institute of Medical Research, 2003–present

Director, Australian Genome Research Facility (2015–2017)

Director, Catalyst Therapeutics Pty Ltd (2012–present)

Director, Cancer Trials Australia Pty Ltd (2009–present)

Director, BACE Therapeutics Pty Ltd (2009–2016)

Chairman & Member, Sansom Institute Advisory Committee, University of South Australia (2006–present)

Director, Julian Clark Consulting Pty Ltd (1999–present)

Chief Executive Officer, Cancer Therapeutics CRC Pty Ltd (2007–2009)

Director, Alchemia Limited (2006-2008)

Director, Genera Biosystems Pty Ltd (2004–2007)

Director, Meditech Research Limited (2004–2006)



Mr Christopher Arnold B Comm, MBA, FCPA, FAIM, MAICD

Director since March 2014

Executive Director, Skin & Cancer Foundation Inc., 2010–present

Director, Melba Opera Trust (2017-present)

Director, Christ Church Grammar Foundation (2012–present)

Director, Skin & Cancer Foundation Inc (2009–present)

Chairman, Telediagnostics Pty Ltd (2010–2017)

Principal, Hodgson Associates (2009-present)

Chairman, Human Variome Project International Ltd (2014–2017)

Director, Human Variome Project International Ltd (2008–2017)

Director Philanthropy Australia (2003–2009)

Director Australian Communities Foundation (1999–2007)



Mr David Polonsky B Bus, CA, TIA, MAICD

Director since January 2015

Director, DRP Consulting Pty Ltd, 1990-present

Director, Moore Stephens (Vic) Pty Ltd (formerly Nexia Melbourne Pty Ltd), (2011–2017)

Director, Private Ancillary Funds



Professor Karin Verspoor BA, MSc, PhD, GCUT

Director since August 2016

Deputy Head of Department (Operations), Department of Computing and Information Systems, University of Melbourne (2015–present)

Fellow, Centre for Business Analytics, Melbourne Business School (2015–present)

Deputy Director, Health and Biomedical Informatics Centre, University of Melbourne (2014–present)

President, Australasian Language Technology Association (ALTA) (2013–2014)

Scientific Director, Health and Life Sciences, National ICT Australia (NICTA) (2012–2014)



Dr Robert Grenfell MBBS, MPH, FAFPHM, MAICD

Director since October 2017

Director – Health and Biosecurity, CSIRO, 2015–present

Director, Grenfell Health Consulting (1997-present)

Director, Maree Stopes Health (2011–2016)

Chair, General Practice Victoria (2007–2010)

Director, General Practice Victoria (1998-2007)

Directors' Report

Meetings attended

The following outlines meetings held and attended by each of the Directors in 2016–17.

Director		Board of Directors		idit & ommittee
	Held	Attended	Held	Attended
Bryan Williams	5	5		
Julian Clark	5	4	4	3
Chris Arnold	5	4		
David Polonsky	5	5	4	4
Karin Verspoor	4	4		
Rob Grenfell	0	0		

The entity is incorporated under the Corporations Act 2001 and is a company limited by guarantee. As such, no shares are issued or held by directors. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the entity. At 30 June 2017 the number of members was 34.

Principal activities

The principal activities of the Company are data sharing that advances health research by linking privacy-protected and ethically approved clinical, imaging, biospecimen and genetic data among a wide network of health collaborators.

During the year there was no significant change in the nature of those activities.

Company's objectives

The company's objectives are to:

- Facilitate internationally competitive medical research into the causes of ill health and disease;
- Provide an ethically approved privacy-protected service to connect data sources;
- Invest in technology development to ensure ongoing alignment with leading technology that supports privacy-protected data connection; and
- Be sustainable in order to fulfill the company's vision and mission and to service the needs of its' members.

To achieve these objectives, the company:

- Supported the Victorian Department of Health and Victorian Cancer Agency by providing data linkage and data management services for state funded cancer research projects;
- Worked with key stakeholders in the health sector to facilitate major research projects in Victoria and Australia;
- Provided ongoing training and support for quality specialist staff committed to providing a technology platform that supports medical research through privacy-protected data connection; and
- Retained a business development focus targeting organisations with the resources to support project work with the company.

Key performance measures

The company measures its own performance through the use of both quantitative and qualitative benchmarks. The benchmarks are used by the directors to assess whether the company's short-term and long-term objectives are being achieved.

2017		2016	
Actual	Benchmark	Actual	Benchmark
34*	38	31	34
36	38	35	38
107	94	85	99
204	182	165	159
19%	20%	19%	21%
	Actual 34* 36 107 204	Actual Benchmark 34* 38 36 38 107 94 204 182	ActualBenchmarkActual34*38313638351079485204182165

*At 30 June 2017 there are 3 non-member collaborator institutions, a total of 37 BioGrid Australia collaborators.

Dividends

The Company Constitution forbids the payment or distribution of any profits, income or assets to the members.

Directors' remuneration

The directors did not receive remuneration from the Company with the exception of reimbursement of expenses relating to their director role.

Indemnification of officers and auditors

During the year the Company paid a premium in respect of a contract insuring the directors of the Company, the Company secretary and all executive officers of the Company and of any related body corporate against a liability incurred as such a director, secretary or executive officer to the extent permitted by the Corporations Act 2001. The Company has not otherwise, during or since the year, indemnified or agreed to indemnify an officer or auditor of the Company or of any related body corporate against a liability incurred as such an officer or auditor.

Critical accounting estimates and judgements

The financial report for the year ended 30 June 2017 has been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.

The Company incurred a loss from continuing operations for the reporting period of \$161,157 for the year ended 30 June 2017, as well as being in a net liability position of \$74,322 as at 30 June 2017.

Likely developments in the operations of the Company and the expected results of those operations in future years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Company.

Notwithstanding the above, the Directors believe it is appropriate to prepare the financial report on a going concern basis given the circumstances summarised below:

- The Company is expected to trade profitably for the current financial year;
- The Directors are continuing to work with key stakeholders who have and continue to show their support for the Company and its future operations;
- The Directors are continuing to work with government (Federal and State), existing and potential customers and clients in industry to increase revenue and margins and expand the services and operations of the Company within Australia and overseas;

- The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of real-time health and medical data for research. Accordingly it is well positioned to take advantage of opportunities as they arise nationally and internationally; and
- The Company continues to develop and improve its national data linkage platform in collaboration with key suppliers using global vendor hardware and software.

Having considered the above factors, the directors have concluded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

Should the Company be unable to continue as a going concern, it may be appropriate to realise its assets and discharge it's liabilities at amounts different to those stated in the financial report.

Events subsequent to balance date

Since the end of the financial year, the Company has received confirmations of support from key stakeholders, which is expected to result in additional income and in an improved position of the Company as at the date of signing this Report.

Auditor's Independence Declaration

The lead auditor's independence declaration for the year ended 30 June 2017 has been received and can be found on page 5 of this report.

Signed in accordance with a resolution, and on behalf of the Board of Directors.

Grym RS Williams

Bryan Williams, Director Melbourne, 16 April 2018



BioGrid Australia Limited 31 136 185 647

Auditor's Independence Declaration

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2017 there have been:

- a) no contraventions of the auditor independence requirements as set out in Section 60.40 of the Australian Charities and Not-for-profits Commission Act 2012 in relation to the audit; and
- b) no contraventions of any applicable code of professional conduct in relation to the audit.

Saward Dawson

Saward Dawson Chartered Accountants

Jetter Tulk

Jeffrey Tulk Partner

Blackburn, Victoria 3130 16 April 2018

20 Albert Street / PO Box 256 Blackburn Victoria 3130 **T:** +61 3 9894 2500 **F:** +61 3 9894 1622 contact@sawarddawson.com.au

 PRINCIPALS: Bruce Saward FCA
 Pe

 Joshua Morse CA
 Je

 DIRECTORS: Cathy Braun CA
 Marie Ickeringill SSA
 Ma

 Murray Nicholls CA
 Vic

Peter Shields FCA Jeff Tulk CA

CA gill SSA Matthew Stokes CA Ills CA Vicki Adams CA CPA CFP® www.sawarddawson.com.au

Liability limited by a scheme approved under Professional Standards Legislation



Financial Report

Statement of Income and Expenditure and Other Comprehensive Income

For the Year Ended 30 June 2017

	Note	2017 \$	2016 \$
Revenue	2	1,507,469	1,572,812
Consultant expenses		(1,367,928)	(1,135,681)
License fees		(89,135)	(103,055)
Administrative expenses		(104,699)	(62,900)
Professional fees		(70,191)	(36,960)
Depreciation		(7,700)	(8,435)
Bank charges		(1,467)	(1,080))
Other expenses		(27,506)	(3,330)
Surplus/(Deficit) from ordinary activities		(161,157)	(221,371)
Other comprehensive income			
Items that will be reclassified subsequently to profit or loss when specific conditions are met		_	_
Total other comprehensive income for the year		-	-
Total comprehensive income for the year		(161,157)	(221,371)

Statement of Financial Position

As at 30 June 2017			
	Note	2017 \$	2016 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	3	33,998	318,912
Trade and other receivables	4	281,842	354,401
Other assets	5	6,445	11,631
TOTAL CURRENT ASSETS		322,285	684,944
NON-CURRENT ASSETS			
Property, plant and equipment	6	4,649	9,054
Intangible assets		49,892	
TOTAL NON-CURRENT ASSETS		54,541	9,054
TOTAL ASSETS		376,826	693,998
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	7	329,348	199,625
Other liabilities	8	121,800	407,538
TOTAL CURRENT LIABILITIES		451,148	607,163
TOTAL LIABILITIES		451,148	607,163
NET ASSETS		(74,322)	86,835
EQUITY			
Accumulated surpluses		(74,322)	86,835
TOTAL EQUITY		(74,322)	86,835

Statement of Changes in Equity

For the Year Ended 30 June 2017		
2017	Accumulated Surpluses \$	Total \$
Balance at 1 July 2016	86,835	86,835
Deficit for the year	(161,157)	(161,157)
Balance at 30 June 2017	(74,322)	(74,322)
2016	Accumulated Surpluses \$	Total \$
Balance at 1 July 2015	134 536	134 536

Balance at 1 July 2015	134,536	134,536
Surplus for the year	(221,371)	(221,371)
Balance at 30 June 2016	(86,835)	(86,835)

Statement of Cash Flows

For the Year Ended 30 June 2017

	Note	2017 \$	2016 \$
CASH FROM OPERATING ACTIVITIES:			
Receipts from customers		1,569,696	1,829,373
Payments to suppliers and employees		(1,551,367)	(1,795,672)
Interest received		_	-
Net cash provided by (used in) operating activities	9	(18,329)	(33,701)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of property, plant and equipment		(1,187)	(6,993)
Payment for intangible asset		(49,892)	-
Net cash used by investing activities		(51,079)	(6,993)
Funds received and held on behalf of Global Variome		66,999	281,184
Funds spent on behalf of Global Variome		(319,163)	_
Net cash used in other activities		(252,164)	281,184
Net cash increase (decreases) in cash and cash equivalents		(284,914)	307,892
Cash and cash equivalents at beginning of year		(318,912)	11,020
Cash and cash equivalents at end of financial year	3	33,998	318,912

Notes to the Financial Statements For the Year Ended 30 June 2017

Note 1 Accounting policies

(a) General information

BioGrid Australia Limited is a Company limited by guarantee, incorporated and domiciled in Australia.

The directors have prepared the financial reports on the basis that the company is a non-reporting entity because there are no users who are dependent on its general purpose financial reports. These financial reports are therefore special purpose financial reports that have been prepared in order to meet the requirements of the Australian Charities and Not-for-profits Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

(b) Basis of preparation

The financial reports have been prepared in accordance with the requirements of the mandatory Australian Accounting Standards applicable to entities reporting under the Australian Charities and Not-for-profits Commission Act 2012 and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members.

Note 1 Accounting policies continued

The financial reports, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs unless otherwise stated in notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements have been rounded to the nearest dollar.

(c) Revenue

Revenue from the rendering of services is recognised upon delivery of the service to customers. Portions that are deemed not yet earned or matched against expenditure are recorded as income received in advance on the statement of financial position. Where the grant or contract relates to support of payments to fixed term employees, these are recognised over an equal period over the life of the contract.

Grant revenue is recognised in the statement income and expenditure and other comprehensive income when the entity obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the company and the amount of the grant can be measured reliably.

Donations are recognised as revenue when received.

All revenue is stated net of the amount of goods and services tax (GST).

(d) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short- term borrowings in current liabilities in the statement of financial position.

(e) Trade and other receivables

Trade receivables include outstanding funds invoiced to customers for membership fees and completed projects or milestones. Receivables expected to be collected within 12 months of the end of the reporting period are classified as current assets.

(f) Plant and equipment

Plant and equipment are measured on the cost basis less depreciation and impairment losses. Cost includes expenditure that is directly attributable to the asset.

Depreciation

The depreciable amount of all plant and equipment is depreciated on a straight-line basis over the asset's useful life to BioGrid Australia Limited commencing from the time the asset is held ready for use.

(g) Intangibles

Amortisation

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, from the date that they are available for use.

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Software

Software has a finite life and is carried at cost less any accumulated amortisation and impairment losses. It has an estimated useful life of between three and five years.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

(i) Income taxes

No current or deferred income tax assets or liabilities have been raised by the company as it is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997. The company is a registered charity under the Australian Charities and Not-for-profits Commission.

(j) Trade and other payables

Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received by the Company during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(k) Global Variome transactions

In 2016, BioGrid entered into an agency agreement to act on behalf of Global Variome in relation to their operations in Melbourne. Total receipts received from Global Variome amounted to \$348,183 and total expenditure incurred was \$319,163. At the end of the 2017 financial year, the arrangement with Global Variome had ceased and it was agreed that the balance of unspent funds of \$29,020 will be subsequently transferred to Melbourne Health who will subsequently take over operations in the next financial year.

The receipt of funds and payments of expenditure is not included in the statement of income and expenditure as the company considers this arrangement to be that of an agency relationship.

(I) Going concern

The company sustained a deficit of \$161,157 for the year ended 30 June 2017. Since then the Directors have been able to negotiate additional support from key stakeholders in the form of premium membership fee income which will enable the Company to trade profitably for the year ending 30 June 2018, and future years. The Company has continued to operate with a positive net cash flow position and this is expected to continue to allow the Company to pay its debts as and when they fall due.

The Directors believe it is appropriate to prepare the financial report on a going concern basis given the circumstances summarised below:

- The Directors are continuing to work with key stakeholders who have and continue to show their support for the Company and its future operations.
- The Directors are continuing to work with government (Federal and State), existing and potential customers and clients in industry to increase revenue and margin expand the services and operations of the Company within Australia and overseas.
- The Company remains the only collaboration network in Australia with the legal and ethical framework to enable the sharing of realtime health and medical data for research. Accordingly it is well positioned to take advantage of opportunities as they arise nationally and internationally.
- The Company continues to develop and improve its national data linkage platform in collaboration with key suppliers using global vendor hardware and software.

Having considered the above factors, the directors have concluded that there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due, and that the company will continue to operate as a going concern.

Should the Company be unable to continue as a going concern, it may be appropriate to realise its assets and discharge its liabilities at amounts different to those stated in the financial report.

	Note	2017 \$	2016 \$
Note 2 Revenue		•	
Operating revenue			
– Commercial-led projects		659,123	843,972
– Member subscriptions		308,280	297,368
– Investigator-led projects		368,750	250,922
– Government projects		120,000	180,000
- Donations		6,794	550
- Interest received		2,083	_
– Other income		42,439	_
Total Revenue		1,507,469	1,572,812
Note 3 Cash and cash equivalents			
Cash at bank		33,998	318,912
	=	33,998	318,912
Note 4 Trade and other receivables			
CURRENT			

CONTENT		
Accounts receivable	281,842	354,401
	281,842	354,401

	Note	2017 \$	2016 \$
Note 5 Other assets			
CURRENT			
Prepayments		6,445	11,631
		6,445	11,631

Note 6 Plant and equipment

Plant and equipment		
At cost	42,908	41,721
Less accumulated depreciation	(38,259)	(32,667)
Total plant and equipment	4,649	9,054

Note 7 Trade and other payables

CURRENT		
Trade payables	191,738	133,188
Accruals	132,774	42,282
GST payable	4,836	24,155
	329,348	199,625

Note 8 Other liabilities

CURRENT		
Industry project income received in advance	83,250	_
Membership income received in advance	9,531	6,354,
Funds repayable to Global Variome	29,020	281,184
Government project income received in advance	_	120,000
	121,801	407,538-

Note 9 Cash flow information

Net surplus/(deficit) for the year	(161,157)	(221,371)
Cash flows excluded from surplus attributable to operating activities		
- Depreciation	5,592	8,435
Changes in assets and liabilities		
– (Increase)/decrease in trade and term receivables	72,558	(4,545)
– (Increase)/decrease in other assets	5,187	(11,631)
– (Increase)/decrease in trade payables	129,723	(274,783)
- Increase/(decrease) in other liabilities	(33,574)	94,854
	18,329	33,701

Note 10 Company details

The registered office of the Company is:

BioGrid Australia Limited Level 8, CMR Building Royal Melbourne Hospital 300 Grattan St, Parkville Victoria 3052

Directors' Declaration

The Directors have determined that the Company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

The Directors of the Company declare that:

- (a) the financial report and notes are prepared in accordance with the Australian Charities and Not-for-profits Commission Act 2012, and;
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable with the continuing support of creditors.

Signed in accordance with subsection 60.15 (2) of the Australian Charities and Not-for-profits Commission Regulation 2013.

Boym RS Williams

Bryan Williams Director 16 April 2018

ma

Julian Clark Director

BioGrid Australia Limited 31 136 185 647



www.sawarddawson.com.au

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of BioGrid Australia Limited (the Company), which comprises the statement of financial position as at 30 June 2017, the statement of income and expenditure and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of the Company is in accordance with the Australian Charities and Not-for-profits Commission Act 2012, including:

a. giving a true and fair view of the Company's financial position as at 30 June 2017 and of its financial performance for the year ended; and

b. complying with Australian Accounting Standards to the extent described in Note 1, and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis of Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Australian Charities and Not-for-profits Commission Act 2012, which has been given

to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

Without modifying our opinion, we draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report is prepared to assist BioGrid Australia Limited to meet the requirements of the Australian Charities and Not-for-profits Commission Act 2012. As a result, the financial report may not be suitable for another purpose.

Responsibilities of Directors for the Financial Report

The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Australian Charities and Not-for-profits Commission Act 2012 and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence

that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Saward Dawson Chartered Accountants

Jetter Tulk

Jeffrey Tulk Partner

Blackburn, Victoria 16 April 2018

20 Albert Street / PO Box 256 Blackburn Victoria 3130 **T:** +61 3 9894 2500 **F:** +61 3 9894 1622 contact@sawarddawson.com.au PRINCIPALS: Bruce Saward FCA Joshua Morse CA DIRECTORS: Cathy Braun CA Marie Ickeringill SSA Murray Nicholls CA Peter Shields FCA Jeff Tulk CA

Marie Ickeringill SSA Matthew Stokes CA Murray Nicholls CA Vicki Adams CA CPA CFP® www.sawarddawson.com.au Liability limited by a scheme approved under Professional Standards Legislation



BioGrid Australia Annual Report 2016-17



BioGrid Australia ABN: 31 136 185 647

Level 8, CMR Building The Royal Melbourne Hospital 300 Grattan Street Parkville 3052 Victoria, Australia

T: +61 (0)3 9342 2690 F: +61 (0)3 9342 8548

enquiries@biogrid.org.au www.biogrid.org.au

Design: Taylor & Grace Published May 2018